Table 2.
Results of protein composition of CSH lesions analyzed by mass spectrometry
| # | Neoplasm | Serum paraprotein | Site (lesion selected by LCM for MS analysis) | MS proteome components
|
IgH sequencing/ somatic hypermutation | |
|---|---|---|---|---|---|---|
| Heavy chain, region | Light chain, region | |||||
|
| ||||||
| 1 | Plasma cell myeloma | IgG lambda | Bone marrow (CSH, no neoplasm) | IgH, V-II* | Absent | NA |
|
| ||||||
| 2 | Lymphoplasmacytic lymphoma | IgM kappa | Lymph node (CSH, no neoplasm) | IgM, C | Kappa, V-III* | Rearranged, productive, IGHV1-2*04/ unmutated |
| IgG, C | Kappa, C | |||||
|
| ||||||
| 3 | Extranodal marginal zone | IgA kappa | Stomach (CSH-rich) | Absent | Kappa, V-I* | NA |
| B-cell lymphoma | Kappa, V-III | |||||
|
| ||||||
| 4Ref16 | Plasma cell neoplasm (MGUS) | IgA kappa | Liver | IgA, IgG | Kappa, V-I* | |
|
| ||||||
| 5Ref17 | Plasma cell neoplasm | IgA kappa | Brain | IgA, C | Kappa V-I* | NA |
| Kappa, C | ||||||
*
Most abundant component
C, constant region; CSH, crystal storing histiocytosis; IgH, immunoglobulin heavy chain; MS, mass spectrometry